menu
    • menu

    Company profile for InflaRx

    NEW Drugs in Dev: 6
    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Veranova: A CDMO that manages complexity with confidence.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    Gangwal Healthcare is powered by innovation, driving health, wellness & healing.

    Virtual Booth

    Contact Supplier

    Aspen API. More than just an API™

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    InflaRx (Nasdaq: IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena an...
    InflaRx (Nasdaq: IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    InflaRxGermany Flag
    Country
    Country
    Germany
    Address
    Address
    InflaRx N.V. Winzerlaer Str. 2 07745 Jena
    Telephone
    Telephone
    +49 (0)3641 508 180
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.inflarx.de/Home.html
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    BD&L Summit

    BD&L Summit

    Not Confirmed

    envelop Contact Supplier

    BD&L Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    InflaRx Data Bolsters Izicopan as Top C5aR Inhibitor
    InflaRx Data Bolsters Izicopan as Top C5aR Inhibitor

    09 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/09/3270828/0/en/InflaRx-Reports-New-Mechanistic-Data-for-Izicopan-Supporting-its-Potential-as-a-Best-in-Class-C5aR-Inhibitor.html

    GLOBENEWSWIRE
    09 Apr 2026
    Share Share
    InflaRx Showcases Vilobelimab's Efficacy In Pyoderma Gangrenosum
    InflaRx Showcases Vilobelimab's Efficacy In Pyoderma Gangrenosum

    30 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/30/3264530/0/en/InflaRx-Highlights-Clinical-Activity-of-Vilobelimab-in-Pyoderma-Gangrenosum-in-Late-Breaker-Oral-Presentation-at-2026-American-Academy-of-Dermatology-Annual-Meeting.html

    GLOBENEWSWIRE
    30 Mar 2026
    Share Share
    InflaRx Reports 2025 Results and Key Milestones
    InflaRx Reports 2025 Results and Key Milestones

    19 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/19/3258900/0/en/InflaRx-Reports-Full-Year-2025-Results-and-Highlights-Key-Achievements-and-Expected-Milestones.html

    GLOBENEWSWIRE
    19 Mar 2026
    Share Share
    Inflarx Present Vilobelimab Ph3 Results For Pyoderma Gangrenosum
    Inflarx Present Vilobelimab Ph3 Results For Pyoderma Gangrenosum

    18 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/18/3258056/0/en/InflaRx-Announces-Late-Breaker-Oral-Presentation-on-Vilobelimab-Phase-3-Results-in-Pyoderma-Gangrenosum-at-2026-American-Academy-of-Dermatology-Annual-Meeting.html

    GLOBENEWSWIRE
    18 Mar 2026
    Share Share
    Inflarx Gets Nasdaq Notice On Minimum Bid Price Requirement
    Inflarx Gets Nasdaq Notice On Minimum Bid Price Requirement

    13 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/13/3255810/0/en/InflaRx-Announces-Receipt-of-Nasdaq-Deficiency-Notice-Regarding-Minimum-Bid-Price-Requirement.html

    GLOBENEWSWIRE
    13 Mar 2026
    Share Share
    InflaRx To Report Full Year 2025 Results On March 19, 2026
    InflaRx To Report Full Year 2025 Results On March 19, 2026

    12 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/12/3254509/0/en/InflaRx-to-Report-Full-Year-2025-Results-on-March-19-2026.html

    GLOBENEWSWIRE
    12 Mar 2026
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search